RECRUITING

Laryngeal Cryotherapy for Refractory Neurogenic Cough

Talk to us

Conditions

Upper-Airway Cough Syndrome

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study aims to evaluate the safety and efficacy of upper aerodigestive tract cryotherapy treatment in patients with refractory neurogenic cough in a prospective pilot study with a validated patient reported outcome measure

Official Title

To Determine the Efficacy of Topical Cryotherapy on Supraglottic Laryngeal Mucosa in the Treatment of Chronic Neurogenic Cough in Adult Patients

Quick Facts

Study Start:2022-12-26
Study Completion:2024-12-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05665244

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adult patients 18 years or older with diagnosis of neurogenic cough
  2. * Neurogenic cough is a diagnosis of exclusion applied to persistent cough (8 weeks or longer)
  3. * Negative workup for other causes, including sinonasal allergies/chronic sinusitis, cough-variant asthma, and GERD
  4. * Patient willing to participate in a clinical trial
  1. * Uncontrolled reflux (scoring on Reflux Symptom index of 13 or higher)
  2. * Vocal fold abnormalities or impairment
  3. * History of asthma or other underlying lung condition not adequately treated or controlled
  4. * Uncontrolled Allergic Rhinitis (Total Nasal Symptom Score \>6, which would indicate moderate disease32)
  5. * Reported symptom of postnasal drip
  6. * Current smoker
  7. * Current neuromodulator medication use
  8. * Patient unwilling to participate in clinical trial or sign an informed consent
  9. * End stage medical disease with poor life expectancy
  10. * Medical instability deemed by the investigators as a contraindication for enrollment
  11. * Abnormal Chest X-ray
  12. * Abnormal pulmonary function testing (PFTs)
  13. * Positive local allergy panel (combined RAST testing)

Contacts and Locations

Study Contact

Shumon Dhar, MD
CONTACT
214-645-7034
Shumon.Dhar@UTSouthwestern.edu
Asha Varghese
CONTACT
214-648-8096
Asha.Varghese@UTSouthwestern.edu

Study Locations (Sites)

UT Southwestern Medical Center
Dallas, Texas, 75235
United States

Collaborators and Investigators

Sponsor: University of Texas Southwestern Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-12-26
Study Completion Date2024-12-30

Study Record Updates

Study Start Date2022-12-26
Study Completion Date2024-12-30

Terms related to this study

Additional Relevant MeSH Terms

  • Upper-Airway Cough Syndrome